Physician profile
Michael Rivera Weiss
NPI 1871516013
$6,286.61
in general payments reported to CMS, 2019-2025
23 companies · $560 in 2025
The $560 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $268 · 2021: $704 · 2022: $607 · 2023: $2,249 · 2024: $691 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,215 · Travel and Lodging: $1,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,215.18 |
| Travel and Lodging | $1,284.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,748.08 | 2021-2025 | Osteocool Rf Ablation System, Kyphon Express II Kyphopak Tray |
| Medtronic USA, INC. | $730.99 | 2019-2020 | |
| Abbvie INC. | $339.56 | 2021-2025 | Botox |
| Boston Scientific Corporation | $306.64 | 2019-2024 | |
| Amgen INC. | $131.02 | 2019-2021 | |
| Covidien LP | $112.00 | 2019 | |
| West Therapeutics Development, LLC | $102.65 | 2019-2021 | |
| Janssen Biotech, INC. | $100.34 | 2019-2022 | |
| Allergan, INC. | $99.26 | 2020-2022 | |
| Flowonix Medical Incorporated | $97.94 | 2019 | |
| Collegium Pharmaceutical, INC. | $81.72 | 2020-2022 | |
| Pfizer INC. | $69.87 | 2019 | |
| Radius Health, INC. | $59.54 | 2022-2023 | Tymlos |
| Abbott Laboratories | $55.27 | 2024-2025 | Proclaim |
| Biohaven Pharmaceutical Holding Company LTD. | $50.45 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leica Microsystems INC. | $37.73 | 2021 | |
| Rock Medical Orthopedics, INC. | $31.69 | 2022 | |
| Nevro Corp. | $28.68 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $27.74 | 2020-2021 | |
| Merz Pharmaceuticals, LLC | $24.04 | 2023 | Xeomin |
| Vertex Pharmaceuticals Incorporated | $21.36 | 2025 | |
| Averitas Pharma INC. | $18.35 | 2025 | Qutenza |
| Glaxosmithkline, LLC. | $11.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rivera Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.